The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

Alkermes wants to augment its pipeline with M&A or licensing deals in serious mental illnesses and substance abuse. “I think ...

E-2086 is under clinical development by Eisai and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate (PTSR) indication ...

Speaking at the JP Morgan Healthcare Conference 2025 yesterday (14 January), Cozadd said: “We’ve got some really exciting ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an ...

An international team of researchers identified over 300 new genetic risk factors associated with depression, offering fresh ...

The majority of individuals with idiopathic hypersomnia report that their disorder affects their social lives and romantic relationships.

Jazz Pharmaceuticals plc recently disclosed its financial update and corporate overview at the J.P. Morgan Healthcare ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) has earned a consensus rating of “Buy” from the seven ratings ...

Detailed price information for Nasdaq Biotechnology Ishares ETF (IBB-Q) from The Globe and Mail including charting and trades.